Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab

被引：126

作者：

Bonig, Halvard ^{[1
]}

Wundes, Annette ^{[2
]}

Chang, Kai-Hsin ^{[1
]}

Lucas, Sylvia ^{[3
]}

Papayannopoulou, Thalia ^{[1
]}

机构：

[1] Univ Washington, Dept Med Hematol, Seattle, WA 98195 USA

[2] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA

[3] Univ Washington, Dept Neurol, Seattle, WA 98195 USA

来源：

BLOOD | 2008年 / 111卷 / 07期

关键词：

D O I：

10.1182/blood-2007-09-112052

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Blockade of CD49d-mediated lymphocyte trafficking has been used therapeutically for certain autoimmune diseases, such as multiple sclerosis (MS). In addition to negative effects on the trafficking of mature lymphocytes to sites of inflammation, CD49d blockade in mice and monkeys rapidly mobilizes hematopoietic stem/progenitor cells (HSPCs) capable of short and long-term engraftment. Here we aimed to ascertain the effects of treatment with antifunctional anti-CD49d antibody in humans (MS patients receiving infusions of the CD49d-blocking antibody natalizumab) on levels of circulating HSPCs after a single dose of antibody or after long-term treatment. On average, 6-fold elevated levels of circulating CD34(+) cells and colony-forming unit-culture (CFU-C) were achieved within 1 day of the first dose of natalizumab, and similar levels were continuously maintained under monthly natalizumab infusions. The blood of natalizumab-treated subjects also contained SCID-repopulating cells. The fate of these circulating HSPCs and their clinical relevance for MS patients remains to be determined.

引用

页码：3439 / 3441

页数：3

共 26 条

[1]

Bonig H, 2007, BLOOD, V110, p661A

[2] Hematopoietic progenitor cells (HPC) from mobilized peripheral blood display enhanced migration and marrow homing compared to steady-state bone marrow HPC [J].

Bonig, Halvard ;

Priestley, Gregory V. ;

Oehler, Vivian ;

Papayannopoulou, Thalia .

EXPERIMENTAL HEMATOLOGY, 2007, 35 (02) :326-334

[3] Collection of hematopoietic stem cells from patients with autoimmune diseases [J].

Burt, RK ;

Fassas, A ;

Snowden, JA ;

van Laar, JM ;

Kozak, T ;

Wulffraat, NM ;

Nash, RA ;

Dunbar, CE ;

Arnold, R ;

Prentice, G ;

Bingham, S ;

Marmont, AM ;

McSweeney, PA .

BONE MARROW TRANSPLANTATION, 2001, 28 (01) :1-12

[4] CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF [J].

Cesana, C ;

Carlo-Stella, C ;

Regazzi, E ;

Garau, D ;

Sammarelli, G ;

Caramatti, C ;

Tabilio, A ;

Mangoni, L ;

Rizzoli, V .

BONE MARROW TRANSPLANTATION, 1998, 21 (06) :561-568

[5] Antibodies to VLA4 integrin mobilize long-term repopulating cells and augment cytokine-induced mobilization in primates and mice [J].

Craddock, CF ;

Nakamoto, B ;

Andrews, RG ;

Priestley, GV ;

Papayannopoulou, T .

BLOOD, 1997, 90 (12) :4779-4788

[6]

DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P401

[7] Peripheral blood CD34(+) cells differ from bone marrow CD34(+) cells in Thy-1 expression and cell cycle status in nonhuman primates mobilized or not mobilized with granulocyte colony-stimulating factor and/or stem cell factor [J].

Donahue, RE ;

Kirby, MR ;

Metzger, ME ;

Agricola, BA ;

Sellers, SE ;

Cullis, HM .

BLOOD, 1996, 87 (04) :1644-1653

[8]

DORIE MJ, 1979, EXP HEMATOL, V7, P483

[9]

Drize N, 1996, EXP HEMATOL, V24, P816

[10]

Foley JF, 2007, MULT SCLER, V13, P1223

← 1 2 3 →